开设104个账户操纵股价、亏损超700万！金城医药董事长被罚后辞职

Core Viewpoint - The chairman of Shandong Jincheng Pharmaceutical Group Co., Ltd., Zhao Yeqing, has been penalized for leading a stock manipulation scheme over nearly three years, resulting in a fine of 1.5 million yuan and a four-year market ban, alongside his resignation from all company positions [1][2][4]. Summary by Sections Stock Manipulation Details - From August 18, 2017, to February 10, 2020, Zhao Yeqing, Wang Zhen, and Liu Feng manipulated the stock of Jincheng Pharmaceutical, controlling a total of 104 accounts for trading [1][2]. - During the manipulation period of 595 trading days, the account group participated in trading for 502 days, buying 119,499,894 shares worth approximately 2.13 billion yuan and selling 107,162,145 shares worth about 1.87 billion yuan [2][7]. - The account group held an average of 18,583,318 shares daily, representing 5.68% of the circulating share capital, with a peak holding of 32,094,771 shares, or 9.04% [2][7]. - Despite the extensive manipulation, the group incurred a loss of 7.392 million yuan [2][7]. Regulatory Actions - The China Securities Regulatory Commission (CSRC) imposed a total fine of 3 million yuan on the three individuals involved, with Zhao Yeqing responsible for 1.5 million yuan, Wang Zhen for 1.2 million yuan, and Liu Feng for 300,000 yuan [2][7]. - Zhao Yeqing received a four-year market ban, while Wang Zhen was banned for three years [2][7]. Company Response and Governance - Jincheng Pharmaceutical stated that the penalties only pertain to Zhao Yeqing personally and do not affect the company's daily operations or management [3][8]. - Zhao Yeqing resigned from his positions due to personal reasons, and the company emphasized that this would not impact the board's operations or the company's normal production [3][8]. - The company plans to complete the election of a new chairman promptly to maintain governance structure integrity [3][8]. Market Impact - Jincheng Pharmaceutical's stock has faced pressure, with a cumulative decline of 26.34% over the past 60 days [4][9]. - As of December 12, the stock price slightly increased by 0.98% to 15.38 yuan, but concerns regarding corporate governance remain prevalent in the market [4][9].